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Peripheral and neuraxial nerve blockades are widely used in the perioperative period. Their values to diminish acute postoperative
pain are established but other important outcomes such as chronic postoperative pain, or newly, cancer recurrence, or infections
could also be influenced. The long-term eﬀects of perioperative nerve blockade are still controversial. We will review current
knowledge of the eﬀects of blocking peripheral electrical activity in diﬀerent animal models of pain. We will first go over the
mechanisms of pain development and evaluate which types of fibers are activated after an injury. In the light of experimental
results, we will propose some hypotheses explaining the mitigated results obtained in clinical studies on chronic postoperative
pain. Finally, we will discuss three major disadvantages of the current blockade: the absence of blockade of myelinated fibers, the
inappropriate duration of blockade, and the existence of activity-independent mechanisms.
1. Introduction
The major interest of regional anesthesia (central or periph-
eral nerve block) in clinical practice remains to replace or
supplement general anesthesia for certain types of surgery
and to provide eﬃcient pain relief in the postoperative
period. Being able to continue the block in the postoperative
period allows amore eﬀective pain control and a reduction of
opioid-related side eﬀects [1, 2]. While the improved patient
comfort is undoubted, an overall improvement in long-
term patient outcome is less evident and combining general
anesthesia with a regional analgesic technique exposes the
patient to the risk of both techniques. Since the concept of
pain treatment as a fundamental human right has emerged,
the use of invasive pain treatment is warranted already for
the improvement of acute postoperative pain treatment [3].
Eﬃcacy of nerve blockade on serious complications in the
postoperative period (major morbidity or mortality) is hard
to demonstrate because of their low incidence [4]. The pos-
sibility of preventing chronic postsurgical pain is becoming a
major issue [3, 5, 6]. In the clinical research literature, there
are only few reports showing a benefit of regional analgesic
techniques on the incidence of chronic postoperative pain
states. Two RCT demonstrated a reduction of the incidence
of chronic postthoracotomy pain in patients treated with
peri- and postoperative epidural analgesia as compared to
patients without postoperative epidural analgesia [7, 8].
Further, a single paravertebral block reduced the incidence
of postmastectomy pain one year following surgery as
compared to a sham puncture [9]. Whereas the incidence
of phantom limb pain after amputation was not influenced
by epidural analgesia [10]. Surrogate outcomes are studied
to increase the indications of regional analgesic techniques:
length of hospital stay, improvement on long-term function
after surgery (in orthopedics) and, newly, cancer recurrence
[11], and reduction in surgical site infection [12]. Experi-
mental research on humans and animals could help to define
more clearly the working hypothesis of clinical trials and
their design.
Current pain treatment should use a mechanistic-based
approach. The best mechanistic knowledge in patient to-
date is obtained from quantitative sensory testing (QST)
where diﬀerent modalities of sensation are tested. There is
a gap between the sensory testing in human and the cellular
and molecular vision oﬀered in an experimental laboratory
setting. The experimental setting also allows diﬀerent types
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of blockade, using drugs with specificities on nerve fiber
types, longer duration, or motor blockade, all of which
cannot be tested on patients unless strong evidence has been
gathered beforehand in experimental studies.
This paper is therefore intended to focus on the eﬀect of
nerve blockade on pain-related behavior and central changes
that occur after peripheral tissue injury in animals (e.g., rats
and mice) and build a bridge to clinical practice. We will
try to point out some discoveries in bench research that
would answer questions or lead to research ideas around the
operating room.
2. Pathophysiology of Peripheral Discharges
and Central Mechanisms of Persistent Pain
2.1. Peripheral Activity and Central Sensitization: A Potential
Contribution to Chronic Postoperative Pain. The potential
benefits of regional analgesic techniques rely on the ability
of local anesthetics to reduce or abolish the peripheral
input electrically transmitted by the nerve. Tissue injury
and/or inflammation (with potential nerve lesion) during
surgery lead to a massive input of action potentials along
the primary aﬀerents. The first relay of the information
in the central nervous system (CNS) is the spinal cord
dorsal horn. The glutamate release at the synapses in the
dorsal horn induces a depolarization in the second-order
neuron. If its amplitude is large enough, it triggers an action
potential that conducts the information to higher centers.
Cumulative aﬀerent inputs gradually sensitize second-order
neurons, which become more reactive to subsequent inputs.
This global process of signal enhancement in the CNS is
called central sensitization and encompasses increased mem-
brane excitability, synaptic eﬃcacy, and reduced inhibition.
Central sensitization and its dependency on primary aﬀerent
activity has been extensively reviewed by Latremoliere and
Woolf [13]. It is often described in 2 temporal phases an
early short lasting, transcription-independent phase caused
by phosphorylation mechanisms and a late longer lasting
phase dependant on transcription and synthesis of new
proteins [14]. Central sensitization is triggered by primary
aﬀerent release of glutamate which binds on postsynaptic
ionotropic (AMPA (amino-3-hydroxy-5-methyl-4-isoxazole
propionate), NMDA (N-methyl-D-Aspartate) and kainate),
and metabotropic (mGluR 1–8, not all expressed in spinal
cord) receptors. Under normal stimulation, the NMDA
receptor is blocked by a magnesium (Mg++) ion in a voltage-
dependent manner. Following sustained activity as in the
case of surgery, the Mg++ block is released and glutamate can
open the NMDA receptor leading to greater calcium entry in
the spinal cord neuron, the first step of central sensitization.
This is enhanced by the neuropeptides Substance P and
CGRP, also released from primary aﬀerents. The increase
in cellular calcium in the dorsal horn neuron appears to
be the trigger for the next step of central sensitization
implicating activation of kinases (protein kinase A (PKA),
C (PKC), or calmodulin kinase II (CaMKII)). These kinases
phosphorylate diﬀerent channels thereby increasing their
traﬃcking to the membrane or changing their biophysical
properties globally enhancing their response. Other targets
in the later phases of the sensitization phenomenon include
mitogen-activating kinases (MAPKs) such as extracellular
signal-regulated kinase (ERK) and transcription factors
finally leading to changes in gene expression.
2.2. Characterization of Spontaneous Discharges after Nerve
Injury. Spontaneous activity occurs from the neuroma
(unregulated regeneration of the nerve stump after injury)
after nerve section [15, 16], and there have been numerous
descriptions of increased peripheral activity after nerve
injury, in diﬀerent neuropathic pain models (Figure 1)
and at diﬀerent timepoints after injury. Most agree that
ectopic activity in primary aﬀerent after nerve injury arises
from multiple sites (the neuroma, along the nerve, or in
the dorsal root ganglion (DRG)) [17, 18]. However, there
are still controversies about which type of fibers (injured
versus noninjured fibers or myelinated versus unmyelinated
fibers) [17]. Since the early recordings following axotomy,
diﬀerent animal models of neuropathic pain (Figure 1) were
developed, many consisting of partial nerve lesions. They
lead to various configurations between intact and injured
nerve fibers. In chronic constriction injuries (CCI, originally
described by Bennett and Xie [19] and modified by Mosconi
and Kruger [20]), mostly myelinated fibers are injured,
leaving neighboring C-fibers relatively undamaged [21]. In
the spinal nerve ligation model (SNL) model [22], intact
roots are in contact distally with the degenerating fibers of
the injured roots and in the spared nerve injury (SNI) model
[23] intact fibers are in contact with the proximal part of the
injured nerves.
Summarizing all studies on peripheral nerve activity
recordings is diﬃcult but we will take out the general
ideas. Most researchers consider A-fibers as the principal
contributors to peripheral ectopic firing following nerve
injury [24–28]. Nevertheless, activity in the unmyelinated
C-fibers was recorded either very early, during the first 15
minutes after a nerve lesion [29], or later, after a few days
[30]. C-fiber activity was also recorded after spinal nerve
ligation in the neighbored intact spinal nerve [31] or after
stimulation of a nerve stump with nociceptive mediators
[32]. This underlines the importance of uninjured fibers as
provider of aﬀerent inputs or of aggravating factors that we
could also use as potential therapeutic target [25, 33, 34].
Is pain-related behavior linked to this ectopic firing?
Indeed in neuropathic models, onset of activity is strongly
related to the generation of pain [17, 31, 35, 36]. Ectopic
discharges were even correlated with pain-related behavior
at the early phase of nerve injury but not later on [37].
In a translational perspective, a nerve blockade, periph-
eral or neuraxial, should therefore cover impulse from both
myelinated and unmyelinated fibers in the postoperative
period. The minimal timeframe until peripheral input is no
longer associated with pain-related behavior after surgery
still has to be defined. Interestingly, for the clinical setting,
Brennan’s group recently paralleled guarding behavior in
rodents to spontaneous pain in postoperative patient. They
were able to show that skin plus deep tissue incision induces
Anesthesiology Research and Practice 3
L3
L4
L5
L6
Rhizotomy
Tibial
nerve
SNL
Sciatic axotomy
SNI
Sural
nerve
CCI
Common
peroneal
nerve
Sciatic
nerve
Saphenous
nerve
Femoral
nerve
Figure 1: Schematic of the major animal models of nerve injury.
Rhizotomy consists of section of dorsal roots; SNL: spinal nerve
ligation, usually L5 or L5 and L6; CCI: chronic constriction injury
consists of loose ligations of the sciatic nerve; SNI: spared nerve
injury, consists of section of the tibial and the peroneal branches
leaving the sural intact.
a guarding behavior and increased spontaneous aﬀerent
activity which was not present in skin incision alone [38].
This brings to attention that spontaneous activity can appear
in an inflammatory model without obvious nerve injury as
seen in our daily surgical activity.
3. Advantages and Limits of Animal Research
The necessity of animal models has always been criticized
[39, 40]. A few well-known failures to translate research
findings into clinical trials, NK-1 antagonists [41], glycine
site antagonist [42], or sodium channel blockers [43] remind
us of the potential gaps between animals and humans. On
the other hand, examples of successful translational research
exist such as conotoxin, which revealed a new mechanism
in pain development and lead to a new treatment [44]. New
compounds are coming to clinical trial, nerve growth factor
(NGF) inhibitor [45, 46], or transient receptor potential
vanilloid receptor 1 (TRPV1) antagonists [47, 48].
Three current limitations in humans are cited by Mogil
[40], (i) single neuron recording which gives valuable
information is not obtainable in human, (ii) functional
magnetic resonance imaging reaches a ceiling and high
activity in neurons cannot be diﬀerentiated, and (iii) some
regions of interest such as the spinal cord dorsal horn or
the DRG are too small to be seen clearly. Therefore, most
human studies characterize pain states and do not look at
anatomical, biochemical, or physiological mechanisms. We
are however able to see an increase in imaging studies which,
together with quantitative sensory testing, represent the best
mechanistic approach feasible in living patients and with
technical improvement some limitations seen above will be
overcome.
An obvious advantage of animals is the standardiza-
tion of the injury and of the genetic and environmental
background and avoiding any social factors. Nerve injuries
on patients are heterogeneous and, therefore, diﬃcult to
study. We will here highlight the advantages and the limits of
animal research specifically looking at nerve blockade issues.
3.1. Advantages of Animal Research
(a) Sustained Block. The influence of duration and initiation
of epidural nerve blockade to prevent chronic changes after
amputation has been studied clinically already 20 years ago
with controversial results [10, 49]. For local anesthetics,
delivery through slow release polymer is complicated and
therefore peripheral or central nerve blockade lasting more
than a few hours in patients implies the placement of a
catheter. The length of a clinical block will depend on
practical issues such as surveillance, costs, risks of catheter
infection [50] or ambulatory surgery. In experimental
research, slow release devices in development can already be
used to block nerves over a few days [35]. By combining a
slow release system (microspheres loaded with bupivacaine
and a small amount of dexamethasone) with an entrapment
(embedding the spheres in fibrin glue inside a silicon tube),
we could achieve a complete sciatic nerve block for a week
with complete recovery thereafter [51].
(b) Selective Block. Asmentioned above, discharges originate
in diﬀerent fiber types depending on the injury model
and timing. In clinical setting pain (nociceptive), specific
blockade is achieved by reducing the concentration of
the local anesthetics. Lots of research is ongoing to dis-
cover blockers whose targets are specifically expressed on
nociceptors such as TRPV1 or specific isoforms of sodium
channels.
TRPV1 can be blocked by an agonist as capsaicin or
resiniferatoxin (RTX) which induces a desensitization of
the nerve fiber for a longer period. In our hands, RTX
directly applied on the sciatic nerve induced a selective
block to heat stimulation for 3 days without aﬀecting the
response to mechanical stimulation or impairing motor
ability. From the 9 voltage-gated sodium channels currently
described (Nav1.1–1.9), Nav1.7, 1.8, and 1.9 are almost
selectively expressed on nociceptors. No specific blocker of
these channels has yet completed clinical trials successfully
but compounds are still being tested [52]. These methods
of selectively blocking nociceptors are not used in the
perioperative setting, yet but in research they are useful tools
to study the influence of selective fibers on the mechanisms
of pain.
(c) Evaluation during the Blockade. Motor/sensitive block
and pain levels can be assessed during peripheral or central
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nerve blockade whereas long-term outcomes as chronic pain
or functional recovery can be checked later. We know many
plastic changes occur in the perioperative period. In animals,
tissue can be harvested during the blockade to study which
mechanism are changed.
(d) Electrophysiological Recordings. The most important
eﬀect of peripheral or central nerve blockade is impeding dis-
charge to pass from periphery to the brain, thereby inhibiting
pain. Fundamental research on pathophysiological mecha-
nisms (ectopic electrical activity-dependant or -independent
changes, location, and timing of nerve activity) can give hints
to clinicians where to block, when, and for how long. Then,
clinical trials based on these mechanisms could be designed.
Besides observational studies on discharge characteristics
in diﬀerent models, electrophysiological recordings allow
to study the eﬀect of blockade on subsequent discharge
patterns.
3.2. Limits in Animal Research. Behavioral studies in animals
are not an easy task. Subject to interobserver and interindi-
vidual variability, they integrate many diﬀerent aspects
of the pain pathways (spinal withdrawal reflexes, spino-
bulbospinal reflexes as jumping, simple innate behaviors as
guarding or licking, or more complicated learned behaviors)
depending on the test used. The limits often put forward in
animal models are the following: assessment of evoked-pain
behavior and not spontaneous pain, no vocalization in the
audible range, or no characterization of symptoms. We have
to be aware of the limitations when we transfer our results to
a clinical application and stay humble when we want to claim
the mechanisms in animals and humans are comparable. We
hope for mechanistic research in human to improve and to
guide our laboratory hypotheses.
4. Clues from the Bench
Detailed eﬀects of blocks on nerve injury models are
summarized in Table 1 and the description of the models in
Figure 1. We will highlight the general ideas below.
4.1. Eﬀects of Timing and Duration of Block on Behavior.
(i) Eﬀect of Timing. The question of whether a nerve
blockade has to be eﬀective before or only after surgery is still
unresolved. Few experimental studies compared the exact
same treatment given before and after lesion. Fletcher et al.
demonstrated a better eﬀect on hyperalgesia when injecting
bupivacaine in the paw before than after carrageenan [53].
The diﬀerence was even sustained when a second dose of
carrageenan was injected a week later [54]. This underlines
that priming of the nociceptive or sensitive system can be
induced by a first injury without being noticed until it is
unraveled by the magnified response to a second insult.
In a model of intravesical acrolein injection, the timing of
lidocaine injection influenced the referredmechanical hyper-
algesia on the hindpaws but not the biochemical changes in
the bladder itself [55], which points to activity dependant
phenomenon or not. Pain mechanisms also change during
development: a nerve blockade was done before or after a
paw incision in 2-week or 4-week-old rat pups, the preinjury
block was only more eﬀective in the 2 weeks old pups
[56]. Short block before injury reduced long-term pain-
related behavior in the CCI model [57–59], but not in the
partial sciatic nerve ligation (PSNL) [57], SNL [60], or spinal
nerve cryoneurolysis models [61]. Sometimes the block only
delayed heat hyperalgesia in the CCI [62] or mechanical
allodynia in the SNL [63]. In the pain clinic, as opposed to
the perioperative setting, preventive block cannot be done
and we want to know if nerve blockade is useful once pain is
established. This is a fundamental pathophysiological issue to
know if peripheral inputs still contribute to maintenance of
pain or if pain has become a self-maintained central process.
Local anesthetic on the dorsal root or spinal nerve after
establishment of neuropathic pain could alleviate transiently
mechanical and cold allodynia after SNL [34, 60] and
inhibiting distal aﬀerent in the CCI model was eﬀective on
heat hyperalgesia [64].
The clinical implication of these results is that it is
probably useful to perform a nerve blockade before the
surgery rather than only starting after. Even if the pain
is already established it is worth to use peripheral nerve
blockade to test if peripheral nerve activity still participates
to the pain process.
(ii) Eﬀect of Duration. Apart from the question of when
to commence the block, the duration of any perioperative
nerve blockade is often questioned. To answer, studies
compare the same treatment for short versus long period.
In animal inflammatory pain models, repeated injections
or bupivacaine-microspheres but not a single injection of
bupivacaine reduced pain behavior [65–67]. In the paw
incision model, which simulates inflammatory postoperative
pain, longer block is more eﬀective for relieving primary and
secondary hyperalgesia [68]. For neuropathic pain, a one-
week-long peripheral nerve blockade in the SNI model did
not prevent pain-related behavior [51], whereas slow release
bupivacaine placed at the time of lesion could prevent it in
the same model and in the CCI [35].
Clinically, the suspicion that a longer block of nociceptive
input could possibly prevent the development of chronic
pain states has newly been discussed in the context of
phantom limb pain after amputation. While older studies
never managed to demonstrate a beneficial eﬀect of epidural
or peripheral nerve blocks, a recent observational study
revealed astonishingly few patients suﬀering from phantom
limb pain one year after lower limb amputation with
prolonged peripheral nerve block performed as peri- and
postoperative pain treatment (median duration of block 30
days) [69]. There are clinical and experimental arguments
in favor of a long-term block but the duration with the best
ratio of risk/benefit has yet to be found.
4.2. Biochemical Changes Aﬀected by Blockade. During the
period of a regional blockade, behavioral analysis is diﬃcult
due to the sensory impairment. Animal research allows
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Table 1: Eﬀect of block on animal nerve injury models. Single means one application, local means on the injury site, and pre-emptive: yes:
before the injury. SNL: spinal nerve ligation, CCI: chronic constriction injury, SNI: spared nerve injury, Seltzer: partial sciatic nerve ligation,
d: day(s), dpi: day(s) postinjury, iv: intravenous, it: intrathecal, ip: intraperitoneal, ttt: treatment, DRG: dorsal root ganglion, SC: spinal cord,
RTX: resiniferatoxin, and TTX: tetrodotoxin.
Author Year Drug Duration Route Preemptive Model
Time of
eﬀect
Eﬀect
Behavioral changes
I. Kissin 1999
N-b-tetracaine single saphenous yes
saphenous
transection
7 dpi
Prevention early
pressure hyperalgesia,
caused hyperalgesia
alone at 10 d
Lidocaine Single saphenous yes
saphenous
transection
1 dpi
Prevention early
pressure hyperalgesia
Y. W. Yoon 1996 Bupivacaine Single
dorsal root L4/5
5 dpi
no SNL L5/6 5 dpi
L5: reduction of
mechanical + cold
allodynia and ongoing
pain; L4: reduction of
mechanical + cold
allodynia
Z. Seltzer 1991 Marcaine Single
sciatic/
saphenous
yes
sciatic/
saphenous
transection
Autotomy is delayed and
its magnitude decreased
P. M.
Dougherty
1991
Lidocaine Single sciatic yes CCI
3 and
10 dpi
Reduction in duration
and magnitude of
thermal hyperalgesia
Lidocaine Single sciatic yes Seltzer
3 and
10 dpi
No eﬀect
S. Abdi 2000 Lido/bupivacaine Single
local before or
4 dpi
yes/no SNL L5/L6 1 d after ttt
Reduction of mechanical
allodynia, no long-term
eﬀect
J. M. Zhang 2000 Lidocaine
During 1
or 8 d
DRG following
injury
no
DRG
compression
1–28 dpi
Reduction of mechanical
allodynia and
hyperalgesia ipsilaterally
with partial eﬀect
contralaterally
L. Luo 1995 Lido/tocainide Single it yes sciatic section
42 d after
ttt
No eﬀect on autotomy
S. R. Chaplan1995 Lidocaine Single
iv, it, local,
28 dpi
no L5/L6 ligation
21 d after
ttt
Reduction of mechanical
allodynia only if plasma
concentration was high
enough, no long-term
eﬀect of local and it
J. Mao 1992 Bupivacaine Single sciatic, 3 dpi no CCI 1 d after ttt
Reduction of thermal
hyperalgesia
J. M.
Gonzalez-
Darder
1985 Mepivacaine Single local yes sciatic section 7–70 dpi
Reduction and delay of
autotomy
M. L. Sotgiu 1995 Lidocaine Single sciatic, iv or iv yes CCI 21 dpi
Reduction in paw licking
during 2-3 weeks, then
no diﬀerence
I. Bileviciute-
Ljungar
1999 Lidocaine Repeat
sciatic contra,
6 + 11 dpi
no CCI 36 dpi
Reduction of thermal
hyperalgesia 3-4 d, small
eﬀect on pressure
stimulation, reduction
of autotomy 36 d
T. Yamamoto 1993
Bupivacaine Single sciatic yes CCI till 14 dpi
Delaying of thermal
hyperalgesia until day 14
Bupivacaine Single
sciatic 15min
post
no CCI 7 dpi
No eﬀect on thermal
hyperalgesia
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Table 1: Continued.
Author Year Drug Duration Route Preemptive Model
Time of
eﬀect
Eﬀect
M. R. Suter 2003 Bupvacaine Long term sciatic/spheres yes SNI 4 weeks
No eﬀect on mechanical
allodynia, thermal
hyperalgesia, cold
allodynia
Y. S. Lyu 2000 TTX Single DRG no
Chung L5
ligation
2 h after ttt
Reduction of mechanical
allodynia, no long-term
eﬀect
S. R. Chaplan2003 ZD7288 Single ip, 7 dpi no SNL L5/6
1 day after
ttt
Reduction in mechanical
allodynia for 2 h, no
eﬀect at 24 h
L. M. Batista 2009 Lidocaine Single sciatic yes CCI, nylon
over 28
days
Reduction of scratching,
thermal hyperalgesia
(noxious and
non-noxious)
I.
Sukhotinsky
2004 Lidocaine Single DRG L4 or L5 no SNL 280min
Reduction allodynia
from 2 to 280 min after
ttt, more eﬀective on L5
than on intact L4
S.
Eschenfelder
2000 Lidocaine Single
dorsal root L5
before section
yes SNL L5 57 dpi
No diﬀerence for
mechanical hyperalgesia
Biochemical or electrophysiological changes
J. M. Zhang 2004
Lidocaine 7 d ip, pump no SNL
7 and
14 dpi
Reduction in tyrosine
hydroxylase staining
Lidocaine 14 d sciatic, pump yes
sciatic
transection
14 dpi
Reduction in tyrosine
hydroxylase staining
C. T. Lin 2009 Lidocaine Single median nerve yes
median nerve
transection
28 dpi
Dose dependent
reduction of injury
discharge pre and post
electrical stimulation
and of NPY and c-fos in
cuneate nucleus
I. Omana-
Zapata
1997 TTX Single intravenoous no
sciatic
transection
4–10 days
Dose dependent
reduction of ectopic
activity
I. Bileviciute-
Ljungar
2001 Lidocaine Single
contralateral
subcutaneous
no CCI 14 dpi
WDR L4/5 neuron
ipsilateral: spontaneous
hyperactivity reduced
for 60 min
L. A. Colvin 2001 Amethocain Single
dorsal roots
L2–6
no CCI 10–14 dpi
No eﬀect on
neuropeptide Y release
in spinal cord
(measurement period of
2 h)
J. Scholz 2005 Bupivacaine 7 d sciatic, spheres yes SNI 7 dpi
Delay in apoptosis of
inhibitory interneurons
in the dorsal horn of
spinal cord
Y. R. Wen 2007 Bupvacaine 3 d sciatic, spheres yes SNI 3 dpi
Inhibition of p38MAPK
activation in microglia
in the spinal cord dorsal
horn
W. Xie 2009 Bupivacaine/TTX Long term
sciatic/DRG
pump 7d
no SNI/SNL 1–10 dpi
TTX: inhibition of NGF
increase (DRG, d3)
OX-42 (SC, d3) and
GFAP (SC, d10); both:
inhibition of glial
activation (DRG, d1–10)
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Table 1: Continued.
Author Year Drug Duration Route Preemptive Model
Time of
eﬀect
Eﬀect
S. I. Chi 1993 Local anesthetic
sciatic or
systemic
no
sciatic
transection
2 and
14 dpi
Reduction in c-fos
immunoreactivity in
dorsal horn of spinal
cord
S. I. Chi 1993 Lidocaine
sciatic or
systemic
yes
sciatic
transection
2 dpi
Reduction in c-fos
immunoreactivity in
dorsal horn of spinal
cord
M. R. Suter 2009 Bupivacaine/RTX 2 d sciatic, spheres yes SNI 2 dpi
Bupi: inhibition of
microglia proliferation
and p38MAPK
activation in dorsal horn
of spinal cord; RTX: no
eﬀect
Mixed outcomes
L. Liang 2010 TTX Repeat sciatic, daily yes
electrical
stimulation
up to
35 dpi
Reduction of mechanical
allodynia,
GFAP-staining on DRG
B. A. Rooney 2007 Lidocaine Single dorsal root yes
bilateral dorsal
root L4/5
section
up to 13
days
No increase in excitatory
amino acid 10 min post
injury, reduction in
mechanical allodynia
W. Xie 2005 Bupivacaine Long term
sciatic, after
lesion
no CCI and SNI
up to 70 d
(CCI),
150 d
(SNI)
Reduction in mechanical
and heat pain for 60 d
(CCI + SNI),
suppression of
hyperactivity at 20–28
dpi in A and C fibers
W. Xie 2005 TTX Long term
sciatic, TTX
(pump 3 or 7 d)
just after lesion
or 10 d later
no CCI and SNI
up to 70 d
(CCI),
150 d
(SNI)
Reduction in mechanical
and heat pain for 60 d
(CCI + SNI), TTX 10 d
eﬀective only during
infusion, suppression of
hyperactivity at
20–28 dpi in A and C
fibers
R. W.
Colburn
1997 Bupivacaine Repeat
spinal nerve
before cut +
before closure
yes
spinal nerve
cryoneurolysis
10 dpi
Reduction of microglial,
but only minimal on
astrocytic response, no
eﬀect on mechanical
allodynia
S. Lee 2007 Lidocaine Single spinal nerve, it yes SNL L5/6 1–4 dpi
Delay in mechanical
allodynia by 1–4 d
C. Sato 2008 Ropivacaine Repeat
epidural, daily
7–17 dpi
no CCI
since
11 dpi
Relief of thermal
hyperalgesia, small
reduction of mechanical
allodynia, NGF increase
in DRG with ropivacaine
W. Xie 2007 TTX 7 d sciatic, pump yes
sciatic
transection
35–49 dpi
Reduction of
hyperexcitability of large
and medium cells and
sympathetic sprouting.
No change in C fiber
through TTX
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observation of changes occurring along the pain pathways
during that period by means of tissue collection and analysis.
Early signs of neuronal activation in the spinal cord assessed
by increased labeling of c-fos (a transcription factor that
leads to expression of proteins) is reduced by nerve blockade
in inflammatory [70] and postoperative [71] models of pain.
Cyclo-oxygenase 2 (COX2) induction and production of
prostaglandin E2 (PGE2) in the CNS is also dependent on
peripheral nerve inputs [72, 73]. In the SNI model, we found
a sciatic nerve blockade which reduces the apoptotic cell
death in the spinal cord dorsal horn. This cell death aﬀects
inhibitory interneurons. It participates in the disinhibition
process involved in the hyperexcitability of the system leading
to pain-related behavior. Sadly, the cell death reduction
is not long-lasting but only postponed until the end of
the block [74]. Microglia and astrocytes, 2 types of glial
cells (nonneuronal cell population of the CNS) have been
implicated in pain processing [75, 76]. They are generally
said to be activated in the context of pain. This activation
was reduced in neuropathic pain model through peripheral
nerve blockade [77, 78].
The idea of a magic bullet curing all pain has van-
ished. Therefore, categorizing specific aspects of sensiti-
zation processes into activity-dependent or -independent
phenomena is useful to know when to use a blockade.
These results also favor the concept of multimodal analgesia
combining peripheral or central nerve blockade to systemic
drugs on various targets.
4.3. Eﬀects of Specific Block. In clinical postoperative setting,
we adjust the concentration of local anesthetic to obtain a
selective nociceptive blockade, which does not block nerve
activity arising in thicker myelinated fibers. The paralysis
of the limb induced by A-β fibers blockade cannot be
accepted for a long period due to risk of sore lesions,
loss of muscle mass hindering rehabilitation, and masking
of complications. Indeed, complications of nerve blockade
(nerve injury, hematoma, infection) are suspected when a
motor deficit appears or persists [79].
In the SNI model, we compared the eﬀect of complete
block (using bupivacaine) to specific nociceptive block with
RTX (TRPV1 agonist, inducing desensitization of the recep-
tor). Microglial activation was reduced only by the complete
block [80]. Tetrodotoxin (TTX) is a sodium channel blocker.
Nociceptive fibers contain TTX-resistant sodium channels,
and, therefore, myelinated fibers are preferentially blocked by
TTX. TTX could prevent neuropathic pain-related behavior
after CCI, SNL, and stimulation-induced pain [35, 81],
but failed to reduced flinching in an inflammatory model
compared to lidocaine [82]. These examples from animal
blockade of specific nerve type highlight the paramount
importance of thick myelinated fibers in sensitization pro-
cesses especially in neuropathic pain. Indeed, we mentioned
ectopic activity in myelinated axons after injury coincides
with tactile allodynia [37].
We believe partial blockade such as currently performed,
especially with an epidural, could be a reason of failure
to prevent chronic postoperative pain despite using pre-
emptive long-term block. Older clinical studies already
pointed the diﬀerential eﬀect of epidural versus spinal inten-
sity of blockade. When both techniques are used at levels
were cold and pinprick sensation is abolished, temporal
summation is conserved in the epidural group, showing
sensitization process might occur in the background of a
painless patient [83, 84].
4.4. Other Eﬀects of Nerve Block. Local anesthetics have many
systemic or local properties besides impeding nerve conduc-
tion through voltage-gated sodium channels inhibition.
(i) The Anti-Inflammatory Eﬀects of Nerve Blockade. The
systemic inflammation tested by the levels of cytokines in the
blood is reduced by bupivacaine, and this eﬀect is systemic as
ipsi, contralateral block and even contralateral intramuscular
injection is eﬀective [85]. In a human model of secondary
hyperalgesia, local anesthetic had a systemic eﬀect [86]
which is clinically relevant as area of hyperalgesia in the
acute postoperative period correlates with the incidence of
postoperative chronic pain [87–89].
(ii) Axonal Transport. Besides electric discharges axonal
transport is another way of signaling a peripheral nerve
injury to the CNS. Experimental axonal transport block
could influence behavioral and glial changes after nerve
injury [90]. Recently bupivacaine has been shown in vivo to
inhibit the retrograde transport of TNFα after an inflamma-
tory insult [91].
These less known pharmacologic properties of local
anesthetics may contribute to the often observed “thera-
peutic eﬀect” of local anesthetics injection in interventional
pain management of certain chronic pain patients, such
as facet joint nerve blocks (a) or epidural infiltrations
(b), were local anesthetic administration alone often show
the same favorable results as their coadministration with
corticosteroids. It is also in this context, that previously
performed randomized “placebo” controlled trials with neg-
ative results comparing the beneficial eﬀect of the combined
administration of corticosteroids and local anesthetics with
patients receiving local anesthetics alone, as for example for
cervical periradicular injections (c), lacked a real placebo
group.
5. Conclusions and Back to Bedside
In clinical practice, nerve blocks are eﬀective for treatment of
acute postoperative pain but their impact on the prevention
of chronic postoperative pain shows conflicting results. This
paper intended to highlight some of the factors found in
experimental studies. The main reason is the blockade lim-
ited to nociceptors with absence of blockade of myelinated
thicker aﬀerents. The latter account for most of the aﬀerent
activity after injury and experimental evidence show they
participate in pain related behavior. Perioperative block
limited to nociceptive fibers reduces the acute pain and
we are maybe missing the sensitization phenomena that
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occur insidiously at the same time through the myelinated
aﬀerents, driving the chronification of the pain process. We
mentioned the recent study with long-term block of all fibers
[69], although only observational, giving encouraging results
on chronic outcomes. For postoperative epidural analgesia, it
will not be possible to fully block the inputs over a few days
but for peripheral nerve blockade a more intense block can
be considered. We have to define the best duration of both
peripheral and epidural blockade balancing the advantages
of inhibiting some central processes with the risks inherent
to these techniques (infection, local anesthetic toxicity, etc.).
With regards to the failure of some regional anesthesia
techniques we have to keep in mind that some changes might
be activity-independent andmust, therefore, be addressed by
other means. This involves multimodal analgesia combining
complementary treatment associating systemic drugs to the
regional technique.
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